HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism.

Abstract
Frontotemporal dementia (FTD) is increasingly recognized as an important type of degenerative dementia but satisfactory pharmacological treatment has not yet been established. We examined the clinical effects of aripiprazole, a new antipsychotic with partial agonistic properties at serotonin 5-HT(1A) and dopamine D(2) receptors, in parallel with cortical glucose metabolism changes. We conducted a follow-up investigation of clinical status and (18)F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) in a 73-year-old male patient with FTD over a 13-month period. Under conventional drug treatment during the first 12 months a marked increase in dementia symptoms was observed. Frontal lobe glucose metabolism clearly decreased during this time period. Under consecutive treatment with aripiprazole a significant and stable improvement of clinical symptoms could be registered, while disturbed frontal glucose metabolism increased significantly. According to this case experience, further investigations should be undertaken to ascertain whether aripiprazole or other atypical antipsychotics with properties to improve impaired dopaminergic transmission in frontal brain regions could qualify for therapy of FTD.
AuthorsAndreas Fellgiebel, Matthias J Müller, Christoph Hiemke, Peter Bartenstein, Matthias Schreckenberger
JournalThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (World J Biol Psychiatry) Vol. 8 Issue 2 Pg. 123-6 ( 2007) ISSN: 1562-2975 [Print] England
PMID17455105 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antipsychotic Agents
  • Blood Glucose
  • Piperazines
  • Quinolones
  • Fluorodeoxyglucose F18
  • Aripiprazole
Topics
  • Aged
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Aripiprazole
  • Blood Glucose (metabolism)
  • Dementia (diagnostic imaging, drug therapy)
  • Fluorodeoxyglucose F18
  • Follow-Up Studies
  • Frontal Lobe (diagnostic imaging, drug effects)
  • Humans
  • Male
  • Mental Status Schedule
  • Piperazines (adverse effects, therapeutic use)
  • Positron-Emission Tomography
  • Psychiatric Status Rating Scales
  • Quinolones (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: